
About Cyrus Biotechnology
Cyrus Biotechnology is a Healthcare company based in Seattle (United States) founded in 2014. Cloud-based protein-modeling software is developed for drug discovery. Cyrus Biotechnology has raised $31.99 million across 11 funding rounds from investors including HHS, Orbimed and Trinity Ventures. The company has 23 employees. Cyrus Biotechnology has completed 1 acquisition, including Orthogonal Biologics. Cyrus Biotechnology offers products and services including IdeS, IL-22 Variant, and sACE2.v2-Fc. Its focus areas include HealthTech, Life Sciences Tech, Research & Development and Drug Discovery. Its legal entity is CYRUS BIOTECHNOLOGY INC. Its competitors include Vividion Therapeutics, Seer and ProteinSimple; 3 of its 3 listed competitors have raised funding.
Company details
Cyrus Biotechnology was founded in 2014 in Seattle, United States, within the biotechnology sector. Cloud-based software for protein modeling in drug discovery is provided. The primary product, Cyrus Bench, is offered as a modified version of the open-source Rosetta molecular modeling tool. This is bundled with essential bio-molecular computation resources, including BLAST, and features a custom user interface to support full utilization.
- Headquarters Seattle, United States
- Employees 23
- SectorsHealthcare
- Website cyrusbio.com
- Social LinkedIn X
- Legal Name Cyrus Biotechnology Inc.
- Total Equity Funding$31.99M (USD)
in 11 rounds
- Latest Funding Round$300K (USD), Grant
Dec 2024
- InvestorsHHS
& 10 more
- Employee Count23
- Investments & Acquisitions
Products & Services of Cyrus Biotechnology
Cyrus Biotechnology offers a comprehensive portfolio of products and services, including IdeS, IL-22 Variant, and sACE2.v2-Fc.
Protein for IgG depletion in autoimmune diseases.
Fusion protein for gastrointestinal and metabolic conditions.
Candidate for COVID-19 prophylaxis in immunocompromised individuals.
Funding Insights of Cyrus Biotechnology
Cyrus Biotechnology has successfully raised a total of $31.99M across 11 strategic funding rounds. The most recent funding activity was a Grant round of $300 thousand completed in December 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $31.99M
- Total Rounds 11
- Last Round Grant β $300,000
- First Round $850,000
(May 2015)
- Investors Count 11
Latest 10 of 11 funding rounds of Cyrus Biotechnology with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec 2024 | $300,000 | Grant | β | β | |
| Sep 2024 | $298,915 | Grant | β | β | |
| Feb 2024 | $2.69M | Series B | β | β | β |
| Dec 2021 | $18.35M | Series B | β | Orbimed, Trinity Ventures | β |
| Apr 2021 | $256,565 | Grant | β | β | |
| Jul 2017 | $8.02M | Series A | β | Trinity Ventures | |
| Feb 2017 | $1.04M | Seed | β | β | β |
| Nov 2016 | $490,000 | Seed | β | β | β |
| Apr 2016 | $535,000 | Seed | β | β | β |
| Mar 2016 | $224,908 | Grant | β | β |
11 investors in total: 11 institutional.
Investors in Cyrus Biotechnology
Cyrus Biotechnology has secured backing from 11 investors, including institutional and venture fund investors. Prominent investors backing the company include HHS, Orbimed and Trinity Ventures.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields. | 1989 | orbimed.com | New York, United States | |
Venture capital firm investing in early-stage technology and real estate companies. | trinityventures.com | |||
Agent Capital is focused on healthcare venture capital investments. | agentcapital.com | Waltham, United States | ||
Venture capital investing and portfolio management services for accredited investors. | av.vc | |||
Early-stage venture capital is provided to US companies across sectors. | wrfseattle.org | Seattle, United States | ||
Early-stage investments are targeted by iSelect Fund in key sectors. | iselectfund.com | St. Louis, United States | ||
| wrule.vc | ||||
Tech & Life-Sciences focused Stage-agnostic VC firm investing in geographies such as North America | springrockventures.com | Seattle, United States | ||
| thewfund.com | ||||
Digital content on health and lifestyle topics is offered. | medtechwings.com |
Investor details for Cyrus Biotechnology
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Cyrus Biotechnology
21 people are tracked at Cyrus Biotechnology (5 in leadership, 5 in board & advisors, 11 in team); the tracked headcount is 23.
| Name | Role | Group |
|---|---|---|
Lucas Nivon | CEO | Leadership |
Eric Tarcha | VP of Drug Discovery | Leadership |
Mark Benjamin | President & EVP Business Development | Leadership |
Erik Procko | Director of Discovery | Leadership |
Yifan Song | Chief Technology Officer | Leadership |
David Baker | Scientific Co-Founder & Advisor | Board & advisors |
Eric Bell | Board Member | Board & advisors |
Chad Waite | Board Member | Board & advisors |
Will Chen | Scientific Advisor | Board & advisors |
Jeff Gray | Scientific Advisor | Board & advisors |
Andy Jerome | Program & Business Development Manager | Team |
Brandon Frenz | Scientific Software Developer | Team |
Max Sauer | Scientist III | Team |
David Thieker | Protein Engineer Scientist | Team |
Benjamin Dutzar | Scientist II | Team |
Ragul Gowthaman | Protein Engineer Scientist | Team |
Emily Frazier | Scientist II | Team |
Galina Stepanyuk | Scientist IV | Team |
Kui Chan | Scientist IV | Team |
Steven Lewis | Scientist | Team |
1 more people are available in the full profile.
Complete people profiles for Cyrus Biotechnology
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Cyrus Biotechnology
Cyrus Biotechnology has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Orthogonal Biologics.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Protein drug manufacturing and research services are provided. | orthogonalbiologics.com | United States | 2020 | Dec 2021 | β’β’β’β’ |
Complete acquisition details for Cyrus Biotechnology
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Cyrus Biotechnology
4 dated milestones of Cyrus Biotechnology across 10 years, from founding to its latest funding, stage changes and deals.
- Founded Cyrus Biotechnology is founded.
- Funding First funding round of $850K.
- Acquisition Acquires Orthogonal Biologics.
- Funding Latest funding round, Grant, of $300K.
Competitors of Cyrus Biotechnology
Cyrus Biotechnology has 3 listed competitors in our database, 3 of them funded. They include Vividion Therapeutics, Seer and ProteinSimple.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| vividion.com | 2016 | Oceanside, United States | $270.5M | 123 | Developing novel drugs based on a proteome-wide ligand and target discovery platform | |
| seer.bio | 2017 | San Francisco, United States | $127.5M | 89 | Proteomics platform developed for early cancer and neurological disease detection. | |
| proteinsimple.com | 2004 | San Jose, United States | $114.29M | 157 | Provider tools to help researchers with protein analysis |
Detailed competitors of Cyrus Biotechnology
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Cyrus Biotechnology
The website of Cyrus Biotechnology (cyrusbio.com) receives about 1.9K visits a month.
- Monthly visits1.9K
▲ 105.1% vs previous month
Websites whose visitors overlap most with Cyrus Biotechnology. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| curibio.com | 100% | 7K | #3,017,939 | View details | |
| parsebiosciences.com | 97% | 62.7K | #493,988 | View details | |
| evotec.com | 81% | 91K | #396,653 | View details | |
| talus.bio | 30% | 4.4K | #4,306,649 | View details | |
| alpenglowbiosciences.com | 30% | 3.7K | #4,504,338 | View details | |
| β’β’β’β’β’β’β’β’β’β’ | β’β’β’β’β’β’.com | β’β’% | β’.β’M | #β’β’β’β’β’ | β |
| β’β’β’β’β’β’β’β’β’β’ | β’β’β’β’β’β’.com | β’β’% | β’.β’M | #β’β’β’β’β’ | β |
| β’β’β’β’β’β’β’β’β’β’ | β’β’β’β’β’β’.com | β’β’% | β’.β’M | #β’β’β’β’β’ | β |
All 17 similar websites and full traffic analytics for Cyrus Biotechnology
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 17 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Life Sciences Platforms & Tools
3 companies that operate in the same segment as Cyrus Biotechnology (Life Sciences Platforms & Tools) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Medidata is recognized as a leading provider of SaaS solutions for clinical research. | 1999 | New York, New York, United States | USD 41.5 M | |||
AI-based solutions for health management are provided. | 2015 | Dallas, Texas, United States | USD 2.8 B | 1,111 | ||
Real-world health data is provided for research and decisions. | 2012 | Menlo Park, California, United States | USD 259.16 M |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Cyrus Biotechnology
Complete news archive for Cyrus Biotechnology
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Cyrus Biotechnology
Cyrus Biotechnology was founded in 2014 and raised its 1st funding round 1 year after it was founded.
Cyrus Biotechnology is headquartered in Seattle, United States. It is registered at Seattle, Washington, United States.
Cyrus Biotechnology is a funded company, having raised a total of $31.99M across 11 funding rounds to date. The company's 1st funding round was a Grant of $224.91K, raised on May 2015.
Cyrus Biotechnology has 23 employees.
Cyrus Biotechnology was founded in 2014 in Seattle, United States, within the biotechnology sector. Cloud-based software for protein modeling in drug discovery is provided. The primary product, Cyrus Bench, is offered as a modified version of the open-source Rosetta molecular modeling tool. This is bundled with essential bio-molecular computation resources, including BLAST, and features a custom user interface to support full utilization.
Cyrus Biotechnology's top competitors include Vividion Therapeutics, ProteinSimple and Seer.
Cyrus Biotechnology offers IdeS, IL-22 Variant, and sACE2.v2-Fc.
Cyrus Biotechnology has made 1 acquisition, including Orthogonal Biologics.
Cyrus Biotechnology has 11 investors. Key investors include HHS, Orbimed, Trinity Ventures, Agent Capital, and Alumni Ventures.
Cyrus Biotechnology operates through Cyrus Biotechnology Inc..
